[Skip to Content]
[Skip to Content Landing]
Article
August 8, 1990

Thrombolytic Therapy of Patients With Acute Myocardial Infarction

Author Affiliations

From the Department of Medicine, Emory University School of Medicine, Atlanta, Ga.

From the Department of Medicine, Emory University School of Medicine, Atlanta, Ga.

JAMA. 1990;264(6):738-739. doi:10.1001/jama.1990.03450060084035
Abstract

In this issue of The Journal, Naylor and Jaglal1 report the results of their meta-analysis of patients with acute myocardial infarction who were enrolled in seven randomized control trials of thrombolytic therapy with either tissue plasminogen activator or streptokinase between March 1982 and November 1987. The authors did a meta-analysis of the number of procedures (cardiac catheterization, coronary angioplasty, or surgical coronary revascularization) performed within 6 weeks of myocardial infarction in the patients in each study treated either with or without thrombolytic therapy. Overall, in the seven trials there was a relative increase of 80% in the number of revascularization procedures (angioplasty or bypass surgery) performed on the patients treated with thrombolytic therapy; the relative increase in the number of procedures was higher in patients treated with tissue plasminogen activator than in patients treated with streptokinase. A similar increase in coronary revascularization procedures after thrombolytic therapy for myocardial infarction

×